BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,777,172 | -16.7% | 26,108 | -0.1% | 0.59% | -13.9% |
| Q2 2023 | $2,132,665 | +8.4% | 26,126 | -1.5% | 0.68% | +3.8% |
| Q1 2023 | $1,967,074 | -10.8% | 26,514 | -0.4% | 0.66% | -14.2% |
| Q4 2022 | $2,205,603 | +10.2% | 26,612 | +277.6% | 0.77% | +7.0% |
| Q3 2022 | $2,002,000 | -18.7% | 7,048 | -0.8% | 0.72% | -12.7% |
| Q2 2022 | $2,463,000 | -20.6% | 7,106 | -0.8% | 0.82% | -8.3% |
| Q1 2022 | $3,102,000 | -16.9% | 7,163 | -0.7% | 0.89% | -9.0% |
| Q4 2021 | $3,734,000 | +5.7% | 7,217 | -0.9% | 0.98% | -8.5% |
| Q3 2021 | $3,531,000 | -0.6% | 7,286 | -7.6% | 1.07% | +1.0% |
| Q2 2021 | $3,551,000 | +16.4% | 7,886 | -1.3% | 1.06% | +11.3% |
| Q1 2021 | $3,050,000 | +19.4% | 7,986 | -0.7% | 0.95% | +14.3% |
| Q4 2020 | $2,554,000 | +28.1% | 8,043 | -0.1% | 0.84% | +17.6% |
| Q3 2020 | $1,993,000 | +74.1% | 8,048 | +37.5% | 0.71% | +1.3% |
| Q3 2019 | $1,145,000 | -7.1% | 5,851 | -0.9% | 0.70% | -6.8% |
| Q2 2019 | $1,232,000 | +3.1% | 5,907 | -1.8% | 0.75% | +0.5% |
| Q1 2019 | $1,195,000 | +36.1% | 6,017 | -0.8% | 0.75% | +20.8% |
| Q4 2018 | $878,000 | -30.5% | 6,067 | -2.0% | 0.62% | -14.4% |
| Q3 2018 | $1,263,000 | +13.7% | 6,190 | -17.6% | 0.72% | +6.6% |
| Q2 2018 | $1,111,000 | -4.4% | 7,510 | -2.4% | 0.68% | -5.6% |
| Q1 2018 | $1,162,000 | +11.5% | 7,696 | -4.3% | 0.72% | +12.7% |
| Q4 2017 | $1,042,000 | +6.7% | 8,046 | -0.4% | 0.64% | +0.8% |
| Q3 2017 | $977,000 | -0.2% | 8,082 | -3.0% | 0.63% | -3.2% |
| Q2 2017 | $979,000 | +16.0% | 8,332 | +0.3% | 0.65% | +12.4% |
| Q1 2017 | $844,000 | -6.4% | 8,307 | -5.2% | 0.58% | -7.6% |
| Q4 2016 | $902,000 | -6.0% | 8,767 | 0.0% | 0.63% | -8.8% |
| Q3 2016 | $960,000 | -4.5% | 8,767 | -1.6% | 0.69% | -9.4% |
| Q2 2016 | $1,005,000 | -6.9% | 8,912 | -21.9% | 0.76% | -6.7% |
| Q1 2016 | $1,079,000 | -16.2% | 11,411 | -20.3% | 0.82% | -16.1% |
| Q4 2015 | $1,288,000 | -3.4% | 14,311 | -0.8% | 0.97% | -6.4% |
| Q3 2015 | $1,333,000 | -6.8% | 14,422 | -0.7% | 1.04% | +4.1% |
| Q2 2015 | $1,430,000 | -4.2% | 14,522 | -2.5% | 1.00% | -3.0% |
| Q1 2015 | $1,493,000 | +7.4% | 14,890 | -1.0% | 1.03% | +11.2% |
| Q4 2014 | $1,390,000 | – | 15,040 | – | 0.93% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |